<DOC>
	<DOCNO>NCT02700919</DOCNO>
	<brief_summary>The purpose study compare efficacy safety BCT197 add standard care adult subject acute respiratory exacerbation chronic obstructive pulmonary disease require hospitalization . Additionally , study characterize pharmacokinetics BCT197 adult COPD . The total duration study 26 week . Subjects receive study treatment administration period 5 day randomization . It expect approximately 255 subject complete study follow-up .</brief_summary>
	<brief_title>Efficacy Safety BCT197 Subjects With Acute Respiratory Exacerbations Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Male female adult Presence active exacerbation ongoing COPD require hospitalization treatment Subjects document diagnosis COPD C D Current smokers exsmokers A documented history least one moderate severe COPD exacerbation 12 month precede Screening Visit require antibiotic and/or systemic corticosteroid . Current regular treatment COPD ( least 2 month prior Screening Visit . Age le 40 year old Current diagnosis asthma Subjects already complete treatment current exacerbation COPD Subjects currently require intensive care unit ( ICU ) and/or mechanical ventilation Received course PDE4 , p38 PDE3/4 inhibitor within respective define washout period .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>